Updates on AHPA activities and resources delivered to your inbox. Subscribe today!
Published: Sunday, April 19, 2020
Recorded: Dec. 17, 2019
Duration: 2 hours
This webinar is designed to help businesses in the dietary supplement industry understand the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that have been the primary focus of recent FDA inspections. This knowledge will assist businesses in better allocating and directing their compliance resources.
Industry experts discuss recent FDA inspections, provide an overview of emerging compliance issues and strategies for responding to an FDA 483 in order to avoid an FDA warning letter. A veteran industry legal expert provides an insider’s view of the current cGMP enforcement landscape and strategies for compliance.
AHPA staff will offer a detailed analysis of the association’s repository of inspection data, widely regarded as the most in-depth in the industry. This includes data compiled from FDA 483 inspection reports, observation forms, and establishment inspection reports (EIRs). Strategies for companies to effectively respond to an FDA 483 in order to avoid getting a warning letter will be offered, and tips for conducting an FDA inspection are also provided.
A 20-30-minute Q&A session follows the speaker presentations to answer attendees' specific questions. Submit your questions before the live event via email to Natasha Weaver.